Surgery Godfather-Chapter 1975 - 1343: Dust Settling (Part 2)

"Mr. Collins, we need to clarify a core concept," Huang Jiacai began, his voice clear and determined, "Based on our agreement with the Sanbo Research Institute and the inherent characteristics of system regulation theory, we do not sell a single ’drug’ or ’therapy license.’ What we offer is a ’system medicine solution.’"

"A mandatory, tiered training and certification system. Any partner must start with certification training from the core team of doctors to ensure understanding of the essence, rather than mechanical operation."

The Chief Legal Counsel added, "Therefore, our cooperation contract is closer to a long-term, deeply binding technical service and co-development agreement. It includes strict implementation standards, data feedback obligations, continuous technical support clauses, and a tiered revenue-sharing model based on efficacy and contribution. A simple upfront payment plus sales sharing model does not apply here."

Members of the Collins team exchanged glances. This was far more complex and in-depth than anticipated. This was no longer about purchasing a product, but about connecting to an ecosystem and accepting a whole new set of rules.

"Training system? Data feedback?" A technical commissioner from Novartis couldn’t help asking, "This involves the ownership of core medical data and patient privacy..."

"This is a repeatedly raised issue, and during the process of popularizing K Therapy, we have encountered such concerns, so please rest assured. All data will undergo strict anonymization and encryption before entering our platform, complying with the strictest regulations worldwide. If there is still hesitation on this point, then there is no basis for cooperation," Ruixing’s Chief Science Officer Chen Zhi took over.

"Data ownership remains with the medical institutions and patients, but the usage rights of processed group data belong to the platform for algorithm optimization. This is a compliance framework designed by legal experts from multiple countries. As for training," he paused, "misunderstanding the system dynamics and misusing the regulation plan poses a far higher risk than traditional targeted drugs. Training is not an obstacle; it is a safeguard, ensuring patient safety and the long-term success of the cooperation project."

Collins listened silently, his fingers unconsciously tapping lightly on the desktop. He had done his homework before coming, knowing the style of Ruixing and Huang Jiacai—precise, assertive, far-sighted, adept at constructing rules rather than just following them. But experiencing it firsthand, he still felt an unprecedented pressure.

"Then, exclusivity?" Collins returned to the original question.

Huang Jiacai smiled slightly, his smile filled with undisputed confidence, "In this emerging field of system medicine, premature and excessive exclusivity is not conducive to the healthy development of the entire ecosystem and may hinder technological progress. We prefer a ’regional deep cooperation’ model. Novartis can have priority cooperation rights and new indication joint development rights for system regulation therapy in the European market, but it is not absolutely exclusive. We retain the possibility of cooperating with other top institutions in specific subfields. Of course, as a deep partner, Novartis will enjoy the most favorable terms in revenue sharing, technological coevolution, and future new therapy expansion."

The meeting lasted the entire morning.

Both sides engaged in in-depth, and sometimes even intense, discussions on framework principles, data standards, training courses, revenue models, intellectual property ownership, especially new discoveries derived from core theories. The thorough preparation, rigorous logic, and deep understanding of theory by Huang Jiacai’s team made a deep impression on the Novartis team. They realized this was not a simple business negotiation but more like participating in designing a blueprint for the future medical business model.

The lunch was a simple buffet, but the exchange continued.

Seemingly casually, Huang Jiacai chatted with Collins about the differences in healthcare systems across various European countries and the localization challenges that system regulation therapy might face, demonstrating his profound understanding of the global market.

In the afternoon, the meeting resumed, involving more specific terms. The lawyers brought by the Novartis team attempted to negotiate more leeway in some legal details, but Ruixing’s legal team could always cite more specific cases or foundational agreement terms to resolve or guide them to solutions more in line with the ’ecosystem’s’ overall interests.

As evening approached, the preliminary framework of the memorandum of understanding for cooperation was finally established. No signature was made, but both sides agreed to draft a detailed list of terms based on this framework within four weeks.

After seeing off the Novartis team, Huang Jiacai returned to his office, slightly loosening his tie in fatigue, but his eyes remained sharp. An assistant served a cup of tea.

"President Huang, Roche will be arriving the day after tomorrow, Glaxo Smith Kline’s Greater China Regional CEO wants to meet next week, and several Silicon Valley biotech investment funds also wish to visit, inquiring about the possibility of early investment in Ruixing or cooperative incubation projects," the assistant reported the schedule.

"Arrange according to the plan. Remember the principle: when pharmaceutical companies discuss specific cooperation, they must follow our model; we don’t meet with investment funds, Ruixing has no plans to go public or introduce investment," Huang Jiacai clearly instructed. 𝘧𝓇ℯ𝑒𝓌𝑒𝑏𝓃𝘰𝘷𝘦𝘭.𝒸ℴ𝓂

At this moment, the Sanbo Research Institute was indeed immersed in a bustling and pure scientific environment.

In the small meeting room, Yang Ping, Tang Shun, Lu Xiaolu, Jiang Jitong, Chu Xiaoxiao, and others were conducting the third round of in-depth analysis revolving around the latest data of a patient named Lina from Heidelberg. The big screen displayed dynamic changes in the metagenomic sequencing of intestinal flora, with abundance curves of various taxa resembling intertwined roller coaster tracks.